Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-cash Items (2016 - 2022)

Arrowhead Pharmaceuticals (ARWR) has disclosed Non-cash Items for 11 consecutive years, with $2.3 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Non-cash Items fell 3.48% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Mar 2022, down 3.48%, and an annual FY2021 reading of $2.5 million, down 14.18% over the prior year.
  • Non-cash Items was $2.3 million for Q1 2022 at Arrowhead Pharmaceuticals, down from $149.3 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $235.5 million in Q4 2020 and bottomed at $2.3 million in Q1 2022.
  • Average Non-cash Items over 5 years is $56.9 million, with a median of $35.7 million recorded in 2018.
  • The sharpest move saw Non-cash Items skyrocketed 9046.42% in 2018, then crashed 98.19% in 2021.
  • Year by year, Non-cash Items stood at $35.7 million in 2018, then crashed by 91.06% to $3.2 million in 2019, then surged by 7291.2% to $235.5 million in 2020, then plummeted by 36.59% to $149.3 million in 2021, then tumbled by 98.43% to $2.3 million in 2022.
  • Business Quant data shows Non-cash Items for ARWR at $2.3 million in Q1 2022, $149.3 million in Q4 2021, and $2.5 million in Q3 2021.